semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Dyslipidemia Associated With Type II Diabetes Mellitus Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms Participants of both sexes, with age greater than or equal to 18 years and less than or equal to 85 years Participants presenting the diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance and previous therapies at a stable dose in the last 3 months HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose > 100 mg/dL at the screening visit Participants with high or very high cardiovascular risk according to the Brazilian guideline on the prevention of cardiovascular diseases in patients with diabetes (2017), which have not reached the goal of LDL-c ≤ 70 mg/dL or ≤ 50 mg/dL, respectively, with lifestyle changes, who are or aren't using low or moderate potency statins BMI (body mass index) > 19 Kg/m2 and ≤ 45 Kg/m2  Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants History of alcohol abuse or illicit drug use Participation in a clinical trial in the year prior to this study Pregnancy or risk of pregnancy and lactating patients Known hypersensitivity to the formula components used during the clinical trial Type 1 diabetes mellitus Fasting blood glucose > 300 mg/dL Risk factors for volume depletion Participants with total cholesterol > 500 mg/dL or triglycerides > 500 mg/dL Impaired renal function and end-stage renal disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Type 2 Diabetes Mellitus Dyslipidemia Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms Participants of both sexes, with age greater than or equal to 18 years and less than or equal to 85 years Participants presenting the diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance and previous therapies at a stable dose in the last 3 months HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose > 100 mg/dL at the screening visit Participants with low or intermediary cardiovascular risk according to the Brazilian guideline on the prevention of cardiovascular diseases in patients with diabetes (2017), which have not reached the goal of LDL-c ≤ 100 mg/dL with lifestyle changes, who are or aren't using low-potency statins BMI (body mass index) > 19 Kg/m2 and ≤ 45 Kg/m2  Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants History of alcohol abuse or illicit drug use Participation in a clinical trial in the year prior to this study Pregnancy or risk of pregnancy and lactating patients Known hypersensitivity to the formula components used during the clinical trial Type 1 diabetes mellitus Fasting blood glucose > 300 mg/dL Risk factors for volume depletion Participants with total cholesterol > 500 mg/dL or triglycerides > 500 mg/dL Impaired renal function and end-stage renal disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Covid19 Type 2 Diabetes T2DM according to the ADA criteria. Patients with long standing diabetes as well as patients with new onset diabetes will be recruited. Patients receiving glucocorticoids for treatment of COVID-19 and manifest plasma glucose levels consistent with diabetes diagnosis also will be included 2. Patients can be drug naïve, receiving oral antihyperglycemic therapy (except pioglitazone), GLP-1 RA or insulin therapy will be allowed to participate in the study 3. COVID-19 infection confirmed with PCR test 4. Age 21-85 years 5. Patients of both sexes will be included 6. In addition to diabetes and COVID-19 diagnoses, patients should manifest at least one of COVID-19 symptoms (Fever, Chills, Headache, Rhinorreah, Cough (dry or with sputum), Sore Throat, shortness of breath, Hemoptysis, Altered mentation, Fatigue/Malaise, Myalgia, Nausea/Vomiting, Diarrhea, Anosmia, Chest pain). 7. Patient receiving other anti-inflammatory therapy for their routine COVID-19 care (e.g. hydroxychloroquine), or antiviral therapy (e.g. remdesivire) will be included in the study and will be evenly randomized amongst the two treatment groups  T1DM 2. Absence of confirmation of COVID-19 infection 3. Age <21 years 4. Presence of heart failure (LVEF<40%) or a history of hospitalization for heart failure 5. Use of diuretics (furosemide or aldactone) for heart disease usually for heart failure. Patients with hypertension receiving diuretic therapy (usually thiazide) will be included in the study 6. Patient on mechanical ventilation or patients whose clinical condition requires mechanical ventilation in the following 24 hours. 7. Patients not expected to survive > 48 hours 8. Patients receiving pioglitazone for the management of their diabetes 9. Patients participating in other research study will be excluded 10. Pregnant women will be excluded from the study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Metabolic Syndrome weight stable > 3 months (changing < 5%) 2. three or more of the following five are met 2.1 waist circumference ≥ 90 cm (men) or ≥ 80 cm (women) 2.2 fasting blood sugar ≥ 100 mg/dl 2.3 fasting triglyceride (TG) level ≥ 150 mg/dl 2.4 fasting high-density lipoprotein (HDL) cholesterol level ≤ 40 mg/dl (men) or ≤ 50 mg/dl (women) 2.5 blood pressure over 130/85 mmHg 3. can consume food that provided in project 4. healthy  consume drugs i.e. weight loss drugs, herbal pills, asthma drugs, steroid drugs, thyroid drugs, insulin injections, SGLT1 inhibitors drugs, SGLT2 inhibitors drugs, sulfonylurea drugs, blood lipid-lowering drugs 2. people who exercise vigorously (> 150 minutes per week) 3. people who are or have weight loss by consuming less than 30% of carbohydrates, or are losing weight by other methods or who have eaten a specific diet as prescribed by a doctor within the past 6 months 4. people who drink alcohol more than once a week 5. people who had a LDL level within 6 months > 190 mg/dl 6. fasting blood glucose levels > 250 mg/dl and using diabetes drugs other than metformin 7. people with heart disease, type 1 diabetes, renal impairment > level 3A 8. history of cancer, lung disease, gastrointestinal disease 9. people who smoke, people with eating disorder, people who have received psychiatric drugs 10. become a volunteer in a research project that is conducting a study related to food consumption 11. people who are unable to keep up with the treatment or are expected to be absent in this area for the next 4 months 12. pregnancy or breastfeeding 13. egg allergy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tricuspid Valve Insufficiency Patient is a candidate for transcatheter tricuspid valve repair as determined by a Heart Team 2. TR grade ≥3+ (5 grade classification) 3. Patient is eligible to receive the device per the current approved indications for use  Tricuspid valve anatomic contraindications, including previous tricuspid valve replacement 2. Severe aortic, mitral, and/or pulmonic valve stenosis and/or regurgitation 3. Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator 4. Any patient considered to be part of a vulnerable population
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 35.0-65.0,  Heart Diseases New York Heart Association (NYHA) (class 1, class II) Class I No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc Class II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Post Coronary artery bypass grafting (CABG) Patients diagnosed with mild to moderate depression on basis of Patient Health Questionnaire (PHQ-9)  Recurrent myocardial ischemia or Infarction (MI) Unstable angina Any diagnosed psychological disease Patients with impaired cognition function Patients with severe life-limiting illness such as cancer, and renal failure Congestive Heart failure
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Endothelial Dysfunction We recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital  History of Coronary artery disease History of Peripheral Arterial Disease History of Heart failure History of Stroke hepatic failure renal failure active neoplasia poorly controlled DM, defined as Hba1C>7%
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pacing-Induced Cardiomyopathy Baseline LVEF>40% Standard pacing indication with >20% VP Functional His bundle lead with confirmed His capture Functional right ventricular lead with myocardial capture  Unable to sign an informed consent form
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 1 Progression Adults with a clinical diagnosis of Type 1 diabetes within the previous 100 days Aged >30 at the time of Type 1 diabetes diagnosis OR (additional early onset Type 1 diabetes cohort) aged ≥18 and ≤30 at the time of Type 1 diabetes diagnosis Insulin treated at the time of recruitment Able and willing to provide informed consent  Pregnancy Known monogenic diabetes Known secondary diabetes (diabetes considered likely due to medication, cystic fibrosis, pancreatitis, pancreatic cancer, pancreatic surgery, hemochromatosis or Cushing's syndrome)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 1.0-20.0,  Type 1 Diabetes Diagnoses of type 1 diabetes with a duration of greater than or equal to 12 months Use of a continuous glucose monitor (CGM) for greater than or equal to 6 months Intention to continue receiving care at the UC Davis Health Pediatric Diabetes clinic  Patient's CGM cannot be uploaded to Glooko
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Covid19 Hospitalized patients with dyspnea and COVID-19  Patients who received positive pressurized oxygen therapy Patients who underwent mechanical ventilation, Atrial fibrillation Complete bundle branch block Significant arrhythmias(complete atrioventricular block, polymorphic ventricular tachycardia, and ventricular fibrillation), Wolff-Parkinson-White syndrome, supraventricular tachycardia Unclear QRS axis orientation. -
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Endocrine System Diseases Nutritional and Metabolic Diseases Diabetes Mellitus, Type 2 Dyslipidemias Screening (Visit 1) 1. Korean men and women aged 40 to 75 2. Patients who have been diagnosed with type 2 diabetes based on clinical judgment and satisfy diabetes diagnosis 3. Those who have no history of statin administration or who are receiving low and moderate-intensity statin, and who have the following laboratory values on an empty stomach Low density lipoprotein-cholesterol (LDL-C) ≥ 100 mg/dL (direct measurement result) mg/dL ≤ Triglyceride (TG) ≤ 499 mg/dL 4. Those with less than 9% HbA1C 5. Those who voluntarily agreed to participate in this clinical trial and signed a written ICF Randomization (Visit 2) 1. Persons with compliance 80% or more during Suvast tablet 5 mg Run-in period and with good TLC by investigator's judgment 2. LDL-C ≥ 70 mg/dL (direct measurement result) at baseline (visit 2) 3. Triglyceride (TG) ≥ 150 mg/dL at baseline (visit 2)  Patients with hypersensitivity to the main ingredient (Ezetimibe or Rosuvastatin) and ingredients of IP 2. Pregnant and lactating women, and women and men of childbearing potential who do not agree to conduct appropriate contraception during clinical trial 3. Patients with Body Mass Index (BMI) < 15 kg/ m2 or > 35 kg/m2 4. Persons with the following medical history or surgical/interventional history Atherosclerotic disease occurring within 24 weeks at screening Myopathy including rhabdomyolysis Patients who have had a history of drug or alcohol abuse, or who have met drug or alcohol abuse within 1 year at screening Major mental illness (depression, bipolar disorder, etc.) Malignant tumor within 5 years at screening 5. Persons with the following comorbidities and laboratory abnormalities CK ≥ 2 X ULN Patients with severe hepatopathy (AST or ALT > 5 X ULN) Patients with unexplained persistent ALT elevation opinion or active liver disease TSH (Thyroid stimulating hormone) > 1.5 X ULN or those who do not maintain stable thyroid stimulating hormone level by investigator's judgment
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Acute Myocardial Infarction Dyslipidemias Age more than 18 years. Both genders are eligible Acute myocardial infarction (STEMI or within 48 hours from the onset of symptoms Baseline LDL-C above 125 mg/dl for those who were not on consistent lipid lowering therapy; or above 100 mg/dl for those who were compliant (≥ 90 days) on moderate intensity statin therapy  Refusal to participate in the study Proved intolerance to statins on previous use Having conditions (or taking medications) that would not allow concomitant safe statins use. [such as patients receiving Cyclosporine Gemfibrozil -Pazopanib - Tipranavir Itraconazole Ketoconazole] Those who are already compliant on high intensity statins Those who are already on statins plus non-statin agent (ezetimibe-PCSK9i-BAS) Known familial dyslipidemia or having TG>500 mg/dl or LDL-C>190 mg/dl which are highly suggestive of familial or secondary causes Pregnant or contemplating pregnancy in the following 12 months. [relevant for females in the child-bearing period]